Here’s what you should know:
1. Mr. Hasegawa was supposed to assume a corporate councilor position following his retirement, but the company’s stakeholders rejected the appointment after Takeda posted “dismal” earnings.
2. Mr. Hasegawa was often advocated for Mr. Weber according to the Nikkei Asian Review.
3. Mr. Weber is facing criticism over Takeda’s falling profitability, recent acquisitions and decreased research-and-development efforts.
4. Takeda has pivoted towards acquiring drug candidates through large price tag acquisitions instead of developing them in house.
More articles on gastroenterology:
FDA accepts application for Salix Pharmaceuticals’ new bowel cleansing preparation — 4 key notes
Potentially infected scope at Kaiser Permanente facility puts 23 at risk & more: 4 GI practices in the news
GI center to know: The Digestive Health Institute of Montana
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
